CBD and depression – what scientific studies say 2026

Depression affects about 280 million people worldwide and is one of the leading causes of disability (WHO, 2023). In Poland, over 30 million prescriptions for antidepressants were issued in 2024, with sales increasing by about 8% year-on-year (NFZ, 2024). Along with the number of publications on cannabidiol, the question from patients is also growing: does CBD help with depression?

This article is not an advertisement. It is a reliable review of evidence from PubMed, Frontiers, Permanente Journal, and pharmacological reviews. We will show what mechanisms CBD has been described by science (5-HT1A, BDNF, anandamide), what the limitations of clinical data in humans are, and why CBD does not replace SSRIs or psychotherapy. We will also discuss interactions with antidepressants through the CYP450 system.

This text is directed at those who want to understand where scientific hypothesis ends and marketing begins. If you are struggling with a low mood, consider this as knowledge support, not a substitute for psychiatric consultation. At the end of the article, you will find phone numbers for helplines operating in Poland 24 hours a day.

KEY INFORMATION
– Depression is a condition that requires psychiatric treatment, psychotherapy, and pharmacotherapy. CBD is not a registered medication for it.
– Most evidence for the antidepressant effects of CBD comes from animal models (Linge et al., Neuropharmacology, 2016; Sales et al., Mol Neurobiol, 2018).
– In the Permanente Journal study 2019 (n=72), a dose of 25-75 mg of CBD daily reduced HAM-A scores in 79% of individuals with anxiety and improved sleep in 67% (Shannon et al., 2019).
– CBD inhibits CYP3A4 and CYP2C19, so it may increase the concentration of SSRIs/SNRIs in the blood (Skelley et al., J Am Pharm Assoc, 2020).
– In crisis, call: 116 123 (Adult Helpline) or 800 70 2222 (24/7 Support Center).

What is depression in DSM-5 and ICD-11 classifications?

Depression is a mental disorder, not a temporary drop in mood. According to DSM-5, a major depressive episode (MDD) requires at least 5 out of 9 symptoms lasting for 2 weeks, including a depressed mood or anhedonia (APA, DSM-5, 2013). ICD-11 WHO classifies it under codes 6A70-6A7Z (WHO ICD-11, 2022).

The illness has three levels of severity: mild, moderate, and severe. In severe cases, psychotic symptoms may appear. Poles tend to underestimate this difference. In a 2023 CBOS study, over 41% of respondents considered that "depression is a weakness of character" (CBOS, 2023). This is a stigma that blocks access to treatment.

Depression does not have a single cause. Genetic factors account for 30-40% of the variance in risk. The rest is due to environment, trauma, somatic diseases, medications, microbiome, and neurobiological factors. The monoamine hypothesis (deficiency of serotonin and norepinephrine) has been dominant for decades, but new models include inflammation and neuronal plasticity.

Most Common Symptoms of MDD

Depressed mood for most of the day. Anhedonia, or lack of pleasure. Sleep disturbances (insomnia or hypersomnia). Changes in appetite and body weight. Psychomotor retardation or agitation. Fatigue. Feelings of guilt or worthlessness. Difficulty concentrating. Recurrent thoughts of death or suicide.

At least 5 of these 9 symptoms, including one of the first two, for 2 weeks, gives a diagnosis of an MDD episode. These are the DSM-5 criteria used by psychiatrists. Single "bad weeks" are not clinical depression. But if the situation persists, do not wait. Consult your primary care physician or psychiatrist.

The Scale of the Problem in Poland

In the EZOP II study, about 4% of adult Poles met the criteria for depression in the last 12 months (EZOP II, 2021). The real number is higher. Only 1 in 4 people with symptoms seeks help. The NFZ reports a steady increase in prescriptions for SSRIs and SNRIs: in 2024, over 30 million packages (NFZ, 2024).

WHO estimates that depression affects about 280 million people worldwide and is one of the leading causes of global disability (WHO, 2023). In Poland, the diagnostic criteria for MDD are met by about 4% of the adult population annually according to the EZOP II study (2021), and antidepressant sales in 2024 exceeded 30 million packages (NFZ).

How does the endocannabinoid system relate to depression?

The clinical endocannabinoid deficiency hypothesis (CECD) suggests that reduced ECS activity may underlie several disorders, including depression, migraines, and fibromyalgia (, 2016). The hypothesis suggests that migraine, fibromyalgia, and irritable bowel syndrome may result from reduced ECS tone., 2016). Lower levels of anandamide and 2-AG in serum have been described in patients with MDD (Frontiers in Immunology, 2018).

The endocannabinoid system regulates mood through CB1 and CB2 receptors and endogenous ligands: anandamide (AEA) and 2-arachidonoylglycerol (2-AG). CB1 is densely distributed in the prefrontal cortex, hippocampus, and amygdala, which are brain areas damaged in depression. This is a biologically coherent premise for research.

Why is the ECS a promising target? Because it acts modulatively, not linearly. Unlike SSRIs, which directly increase serotonin, the ECS fine-tunes the signaling of other pathways: serotonergic, GABAergic, glutamatergic, and dopaminergic. CBD enters this system indirectly, and this is a key difference from classical monoaminergic drugs.

Anandamide, FAAH, and Mood

Anandamide is an endogenous CB1 agonist, referred to as the "bliss molecule." It is broken down by the FAAH enzyme (fatty acid amide hydrolase). In individuals with FAAH gene polymorphism (lower enzyme activity), lower anxiety levels and better stress tolerance have been described (PubMed, 2019). This is biological evidence for the role of the ECS in mood regulation.

CBD indirectly raises anandamide levels by weakly inhibiting FAAH and blocking intracellular transport. This is one of the mechanisms for which cannabidiol is being studied in the context of anxiety, PTSD, and depression. A key caveat: this effect has been well documented in vitro and in animals, but less so in humans at typical oral doses.

Inflammation and Depression

Depression is increasingly described as a disorder with a neuroinflammatory component. Elevated IL-6, TNF-alpha, and CRP levels are observed in patients with MDD (Frontiers in Immunology, 2018). CBD exhibits immunomodulatory and anti-inflammatory effects, suggesting an additional pathway of potential influence on mood through the gut-microbiome-brain axis.

However, this is a hypothesis, not a clinical certainty. Immunological studies show biochemistry but do not demonstrate that lowering cytokines in a specific patient translates into improved depression symptoms. Classical RCTs with CBD as monotherapy for depression are still in the design phase.

If you want to better understand how CBD differs from THC and CBG at the receptor level, check out our comparative guide.

What is the mechanism of CBD's action on mood - 5-HT1A, BDNF, and neurogenesis?

CBD does not strongly bind to CB1 or CB2. It acts through about 65 identified molecular targets, including indirect activation of the serotonin receptor 5-HT1A (Linge et al., Neuropharmacology, 2016). This is the same receptor activated by buspirone and partially by SSRIs in the cascade of mood and anxiety regulation.

Linge and colleagues in 2016 showed in an animal model (Olfactory Bulbectomy, OBX) that CBD induced a rapid effect similar to imipramine, and the effect disappeared after blocking the 5-HT1A receptor with the antagonist WAY-100635. This is the first biologically coherent mechanism. But note: the OBX model involves rodents, not humans.

Sales and colleagues in 2018 demonstrated in mice that a single dose of CBD increased BDNF and synapsin expression in the prefrontal cortex and hippocampus after 30 minutes (Sales et al., Molecular Neurobiology, 2018). BDNF is a growth factor associated with synaptic plasticity, and its deficiency is described in MDD.

Mechanism 1: 5-HT1A Receptor

The 5-HT1A receptor is coupled with G-protein. Its activation in the dorsal raphe nuclei decreases serotonin release (autoreceptor), while in the cortex and hippocampus, it increases postsynaptic inhibition. CBD is a weak, indirect agonist of this receptor in in vitro and in vivo studies on rodents.

What does this mean for humans? A hypothesis. If the mechanism works in humans at oral doses, CBD could modulate anxiety and mood similarly to buspirone-type medications. However, there is a lack of large RCTs measuring 5-HT1A occupancy in humans after oral CBD. This is a knowledge gap that should not be ignored.

Mechanism 2: BDNF and Synaptic Plasticity

BDNF (Brain-Derived Neurotrophic Factor) supports neuron survival and the formation of new connections. Patients with depression have reduced serum BDNF levels. SSRIs increase BDNF after 4-6 weeks, which is associated with a delayed therapeutic effect. CBD in animal models raises BDNF more quickly, within hours, but the effect in humans has not been confirmed.

Sales et al. (2018) also describe an increase in neurogenesis in the hippocampus after chronic administration of CBD to mice. This is another argument for its antidepressant potential, but the doses scaled to body weight often exceed what humans routinely use. A dose of 30 mg/kg in mice roughly corresponds to 2-3 mg/kg in humans after allometric scaling.

Mechanism 3: Anandamide and ECS

CBD increases anandamide levels by inhibiting FAAH and blocking transport. Higher AEA activates CB1 in limbic areas. This pathway partially overlaps with 5-HT1A and creates a "second chain" of action on mood, which explains the pluralism of CBD's molecular targets.

Unique observation: CBD does not have a single "antidepressant mechanism." Rather, it has three overlapping pathways: the indirect 5-HT1A, modulation of the ECS by anandamide, and increased BDNF. This is how many traditional antidepressants work, but classic SSRIs hit the target sharply and selectively. CBD rather "conducts the orchestra" than plays solo - this may explain its milder profile and simultaneously weaker efficacy in monotherapy.

What do animal studies say - Linge 2016 and Sales 2018?

Most evidence for the antidepressant effects of CBD comes from rodent models. In the Forced Swim Test (FST), CBD at doses of 30-100 mg/kg shortened the immobility time, which is interpreted as an antidepressant-like effect (Crippa et al., Curr Pharm Des, 2018). Linge 2016 showed a rapid effect after a single dose.

Animal models have advantages and limitations. They allow for precise control of variables: dosage, timing, biochemistry. But animals do not "experience" depression in a phenomenological sense. The FST test measures behavioral activity, not mood. Therefore, preclinical results are never direct evidence of clinical effect in humans.

Linge 2016 - OBX model and 5-HT1A

Linge et al. (Neuropharmacology, 2016) applied the olfactory bulbectomy model in mice, which induces behavioral and neurochemical changes similar to depression. A single dose of 50 mg/kg of CBD reversed behavioral deficits as effectively as imipramine. Importantly, the effect was blocked by the 5-HT1A antagonist WAY-100635.

This is an elegant confirmation of the mechanism. However, a dose of 50 mg/kg in mice corresponds approximately to 4 mg/kg in humans, which is about 280 mg for a 70 kg person. Most users take 25-50 mg daily. Scaling matters - this is one of the reasons why preclinical results do not translate 1:1 into clinical practice.

Sales 2018 - BDNF, mTOR, and plasticity

Sales et al. (Mol Neurobiol, 2018) demonstrated that CBD activates the mTOR pathway and raises BDNF in the prefrontal cortex and hippocampus. The effect correlated with improvement in the FST in rats. Interestingly, the mechanism resembles the rapid action of ketamine, which also acts through mTOR and synaptic synthesis.

This is one of the most frequently cited neurobiological pieces of evidence for the potential of CBD. However, the authors explicitly stated that rodent data require validation in humans. By 2026, such validation is lacking in the form of a large RCT measuring BDNF in patients with MDD taking oral CBD.

Other Models and Doses

In the chronic mild stress (CMS) model, CBD at doses of 7-30 mg/kg reversed anhedonia in rats. In the tail suspension test, doses of 3-30 mg/kg produced effects similar to antidepressants. Crippa et al. (2018) summarize that the spectrum of effective doses in rodent models is broad and biphasic (inverted U curve).

In the OBX model in mice, CBD at a dose of 50 mg/kg reversed depressive deficits as effectively as imipramine, and the effect disappeared after blocking the 5-HT1A receptor with the antagonist WAY-100635 (Linge et al., Neuropharmacology, 2016). This is the first coherent mechanistic evidence, but it requires validation in humans in randomized clinical trials.

What do studies say about humans – Permanente Journal, Crippa, Skelley, Pinto?

Here the situation is different from animals. RCTs specifically for depression are few. The most frequently cited human study did not focus on depression as the primary endpoint, but on anxiety with accompanying sleep disorders (Shannon et al., Permanente Journal, 2019). This must be honestly stated before presenting the results.

Permanente Journal 2019: 72 adults with anxiety (n=47) or sleep problems (n=25), psychiatric clinic in Colorado. Dosing 25 mg of CBD in the evening, in selected cases up to 175 mg daily. After the first month, HAM-A scores decreased in 79% of patients. Sleep improved in 67% in the first month (Shannon et al., 2019). Limitation: retrospective, open study, no placebo.

Crippa et al. (Curr Pharm Des, 2018) is a review, not a study. The authors summarize the evidence on CBD in anxiety, depression, and schizophrenia. Conclusion: CBD shows a promising anxiolytic and potentially antidepressant profile, but data in humans with MDD are preliminary and do not justify its use as monotherapy.

Permanente Journal 2019 – Shannon et al.

This is the most frequently cited pragmatic study. 72 patients. 25-175 mg of CBD daily. Observation time 3 months. Results: anxiety reduction in 79% in the first month, sleep improvement in 67%. Only 3 individuals reported side effects (fatigue). Most maintained benefits over the next 2 months.

Strengths: real clinical conditions, long observation period, functional data. Weaknesses: lack of randomization, lack of placebo, lack of a group with MDD as the main diagnosis. Most patients had anxiety, and depression was a comorbidity. This is 'real-world' data, not RCT.

Crippa et al. 2018 – review

Crippa, Guimaraes, Campos, and Zuardi analyzed about 130 publications. Conclusion: CBD has a pharmacological profile consistent with hypothetical anxiolytic and antidepressant action, based on preclinical data and several small studies in humans. There is a lack of RCTs with a large sample and appropriately long follow-up.

The authors highlight three gaps: (1) lack of data for severe episodes of MDD, (2) lack of data for long-term therapy (over 6 months), (3) lack of comparative data with SSRIs head-to-head. By 2026, these gaps largely remain, despite the increase in publications.

Pinto 2020 and Skelley 2020 – safety and interactions

Pinto and colleagues (J Cannabis Res, 2020) summarized the safety profile of CBD: well tolerated at doses up to 1500 mg daily in adults. The most common side effects: drowsiness (15-30%), diarrhea (10-20%), changes in appetite, elevated liver enzymes at high doses.

Skelley et al. (J Am Pharm Assoc, 2020) is a review of CBD interactions with medications. Key conclusion: CBD is a strong inhibitor of CYP3A4, CYP2C19, and CYP2C9. These enzymes metabolize most SSRIs, SNRIs, and TCA. Combining CBD with antidepressants may raise drug concentrations in the blood and intensify side effects.

You can find a complete list of medications that require caution when combined with CBD in our separate interaction guide.

What CBD definitely won't do for depression?

The list of things that CBD does NOT do is longer than the list of confirmed effects. CBD is not a registered antidepressant by EMA, FDA, or the Polish URPL. The only indications approved by the FDA for CBD (under the name Epidiolex) are treatment-resistant childhood epilepsies: Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis (FDA, 2018).

CBD does not replace SSRIs, SNRIs, TCAs, or psychotherapy. NICE and APA indicate pharmacotherapy (mainly SSRIs), cognitive-behavioral therapy, interpersonal therapy, and in severe cases, ECT or TMS as first-line treatments in MDD (NICE NG222, 2022). CBD does not appear in any official recommendations as monotherapy for depression.

CBD is not a 'quick fix' medication. Some studies suggest a rapid effect on acute anxiety, but effects on mood require weeks of regular use, similar to classic antidepressants. Marketing claims like 'sorrows disappeared with the first drop' are false. This is not how brain pharmacology works.

CBD does not prevent suicidal thoughts

There is a lack of data. If suicidal or resignation thoughts arise, any delay is dangerous. Do not hesitate for CBD. Call 116 123 (Helpline) or 800 70 2222 (Support Center 24/7), or 112 if the threat is immediate. This is the only correct response, regardless of whether you use CBD or not.

CBD does not replace psychotherapy

Cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT) have numerical evidence of effectiveness comparable to SSRIs in mild and moderate depression (APA, 2019). CBD will not change thought patterns, teach emotional regulation, or process trauma. These are the tasks of psychotherapy.

CBD is not a 'natural Prozac'

This is a popular marketing slogan that ignores the facts. Fluoxetine has 50 years of clinical data, dozens of RCTs, strict indications, and known side effects. CBD has a different profile, less data, and is not a pharmacological substitute for SSRIs. Comparing them at the advertising level is misleading and potentially harmful.

From the Bucha editorial office: In our conversations with clients, questions about CBD for depression are among the top five most common. Our first response is always to ask about a psychiatrist. If the person does not yet have a diagnosis, we refer them to POZ or ZdrowiePsychiczne.pl. CBD is not a product we recommend 'for depression'. We always emphasize that it is a potential supplement, after consulting with the treating physician, never a substitute for treatment.

What are the interactions of CBD with antidepressants – SSRI, SNRI, TCA?

This is the most important practical chapter. CBD is a strong inhibitor of CYP3A4, CYP2C9, and CYP2C19 (Skelley et al., J Am Pharm Assoc, 2020). These three enzymes are responsible for the metabolism of most psychiatric medications. Inhibition of these can raise drug concentrations in serum by 30-100%, increasing the risk of side effects.

CYP inhibition is not a hypothesis. It is a measured, clinically significant phenomenon. In the case of Epidiolex (pure CBD), the FDA requires monitoring of clobazam, valproate, and other antiepileptic drugs precisely because of this interaction. Antidepressants fall into the same risk category.

SSRI – sertraline, escitalopram, fluoxetine, paroxetine, citalopram

All SSRIs are metabolized at least partially by CYP2C19 and/or CYP3A4. Sertraline has an active metabolite (norsertraline). Escitalopram is sensitive to CYP2C19. Inhibition of this enzyme by CBD may raise drug concentrations, increase side effects (nausea, diarrhea, sedation), and theoretically increase the risk of serotonin syndrome.

Practical implications: if a patient is taking SSRIs and wants to add CBD, the decision is made by the psychiatrist. Low doses of CBD (10-25 mg) likely have minimal clinical impact on most individuals. Higher doses (above 100 mg daily) require in-depth pharmacological assessment.

SNRI – venlafaxine, duloxetine, milnacipran

Venlafaxine and duloxetine are primarily metabolized by CYP2D6 (CBD weakly inhibits it) and CYP3A4. A clinically significant interaction is less obvious than for SSRIs, but not excluded. Patients on SNRIs should treat the addition of CBD as a decision requiring consultation with a physician.

TCA – amitriptyline, clomipramine, doxepin, opipramol

Tricyclic antidepressants are metabolized by CYP2C19, CYP3A4, and CYP2D6. They have a narrow therapeutic index and well-known cardiotoxicity at high concentrations. Combining with CBD is particularly risky here. Without monitoring drug concentrations in the blood, it is better to avoid this.

Other groups – mood stabilizers, atypical antipsychotics

Patients with bipolar disorder often take valproate, lamotrigine, lithium, or quetiapine. CBD interacts with valproate (increased risk of hepatotoxicity), with lamotrigine (via UGT), and with quetiapine (via CYP3A4). Each such combination requires close psychiatric supervision and often monitoring of liver enzymes.

CBD is a clinically significant inhibitor of CYP3A4, CYP2C9, and CYP2C19 – enzymes that metabolize most SSRIs, SNRIs, and TCAs (Skelley et al., J Am Pharm Assoc, 2020). Combining these groups may increase drug concentrations by 30-100% and intensify side effects, so the decision to supplement requires the approval of the attending psychiatrist.

When does CBD make sense as therapy support, and when does it not?

This question requires an honest answer. CBD is not registered as a medication for depression. At the same time, some patients use it as an adjunct to treatment, most often to support sleep and reduce accompanying anxiety. According to surveys by Project CBD, about 17-22% of CBD users indicate 'low mood' as one of the reasons (Project CBD, 2023).

Situations in which CBD is considered: anxiety accompanying depression, sleep problems, somatic symptoms of stress, chronic pain affecting mood. Most often in the context of being the 'last piece of the puzzle' in stable antidepressant therapy. This is a different situation than 'depression that I treat with CBD'.

Situations where CBD does NOT make sense: severe depressive episode, suicidal thoughts, psychotic depression, bipolar disorder in manic or mixed phase, pregnancy and breastfeeding, children and adolescents without psychiatric indication, patients on polypharmacy (more than 5 medications).

When it CAN be considered (with a doctor)

Stable SSRI or SNRI therapy for over 6 months, good clinical response, but persistent sleep problems or subclinical anxiety. The patient is in contact with a psychiatrist. No significant liver diseases. No high-risk interactions. In such a situation, low doses of CBD (10-25 mg daily) may be considered as an adjunct to primary therapy.

When it MUST NOT be considered

Freshly diagnosed depression. Untreated suicidal thoughts. Lack of contact with a psychiatrist. Polypharmacy without monitoring. Advanced liver disease. Pregnancy. Breastfeeding. Age under 18 without medical indication. In these situations, CBD may do more harm than good, regardless of marketing.

When to see a specialist – red flags

Low mood lasting more than 2 weeks. Anhedonia. Sleep disturbances (insomnia or hypersomnia). Changes in appetite and weight. Slowing down. Feelings of guilt. Problems with concentration. Thoughts of death. If you recognize 2-3 of these symptoms in yourself, make an appointment with POZ or a psychiatrist. This is not a 'whim' – it is the standard procedure according to APA and NICE guidelines.

What are the CBD doses appearing in studies – 25-300 mg?

In clinical studies on anxiety and mood, the most commonly encountered doses of CBD are 25-300 mg daily. In the Permanente Journal 2019, the typical dose is 25 mg in the evening, sometimes up to 175 mg daily (Shannon et al., 2019). In the study by Bergamaschi et al. on social anxiety, a single dose of 600 mg reduced anxiety before public speaking (Bergamaschi et al., Neuropsychopharmacology, 2011).

The dose-response curve for CBD in anxiety is ambiguous. In one study on social anxiety, a dose of 300 mg had the greatest effect, while 600 mg and 900 mg were less effective. This is a typical 'inverted U' pattern for receptor modulators. The practical consequence: a higher dose does not always mean a better effect.

How to calculate the dose from oil

5% oil: 1 drop = about 2.5 mg of CBD. 10% oil: 1 drop = about 5 mg. 15% oil: 1 drop = about 7.5 mg. To achieve 25 mg daily, you need 5 drops of 5% oil or 3 drops of 10% oil. To achieve 100 mg daily, you need about 20 drops of 5% or 10 drops of 10%, usually in two divided doses.

A complete dosing guide for CBD with a calculator can be found in our separate article.

The "start low, go slow" protocol

Step 1: 5-10 mg in the evening for 3-5 days. Step 2: if no effect, increase to 15-20 mg. Step 3: if still no effect, to 25-30 mg. Step 4: if still no effect after 4 weeks, consult a doctor. Do not jump straight to 100 mg, as this is not a sleeping pill and does not work on the principle of 'more = stronger'.

In the morning or evening

The sedative profile of CBD (especially in broad spectrum with myrcene) suggests evening dosing. Some people split the dose: 1/3 in the morning, 2/3 in the evening. For those with morning anxiety, a dose of 5-10 mg in the morning can be helpful. The decision is individual and should be based on personal observation in the first 2 weeks.

What does the safety of CBD look like and monitoring during therapy?

The safety profile of CBD is relatively good, as confirmed by WHO and Pinto et al. CBD is well tolerated at doses up to 1500 mg daily in adults (Pinto et al., J Cannabis Res, 2020). Iffland and Grotenhermen (Cannabis and Cannabinoid Research, 2017) summarized over 130 publications – safety profile confirmed, but there are reservations.

The most common side effects: drowsiness (15-30%), dry mouth, diarrhea, changes in appetite and weight, fatigue. At higher doses (above 300 mg daily), there is an increase in liver enzymes ALT and AST in 5-15% of patients. This requires regular laboratory tests with long-term use.

What to monitor before and during supplementation

Before: consultation with the attending physician, liver tests (ALT, AST, GGTP, bilirubin), TSH, list of all currently taken medications. After 3 months: repeat liver tests, symptom assessment, interaction assessment. After 6 months: full re-evaluation of whether supplementation makes sense to continue.

In patients with liver disease, kidney failure, severe CYP damage, CBD may be contraindicated or require significantly lower doses. This decision should not be made independently. A hepatologist or psychiatrist should be involved in the plan.

Product quality – certificate of analysis (COA)

Every CBD oil should have a laboratory analysis certificate (Certificate of Analysis) confirming CBD content, no THC above 0.3%, and no heavy metals or pesticides. Without a COA, you do not know what you are really taking. This is the minimum quality that is worth checking with the manufacturer.

We described the differences between isolates, broad spectrum, and full spectrum in our guide to types of CBD extracts.

Special Patient Groups

Pregnancy and breastfeeding: lack of safety data, FDA and EMA advise against. Children and adolescents: only within Epidiolex under medical supervision for epilepsy, not as a mood supplement. Older adults (65+): caution with dosing, frequent polypharmacy, higher risk of interactions. Patients with liver diseases: individual assessment by a hepatologist.

Bucha data Q1 2026: In the group of customers who indicated 'mood support' as the purpose of purchase in post-sale surveys, about 64% report concurrent use of SSRIs or SNRIs, and 81% confirm prior consultation with a doctor before starting supplementation. This is a significantly higher percentage of consultations than the market average, which we attribute to the informative nature of our communication.

What are the helplines and crisis support in Poland?

This is the most important chapter of this article. If you have thoughts of resignation or suicide, do not read further, just call. In Poland, several free, anonymous support lines are available 24 hours a day. According to GUS, in 2023, there were 4669 suicides, and depression is one of the main risk factors (GUS, 2023).

Emotional Crisis Helpline for Adults – 116 123

Free, anonymous line active daily from 14:00 to 22:00. Run by the Institute of Health Psychology. The number 116 123 is one of the EU-wide psychological support numbers. Consultants are qualified psychologists and psychotherapists.

Support Center for People in Mental Crisis – 800 70 2222

Free, anonymous support available 24 hours a day, 7 days a week. For adults. Run by the ITAKA Foundation. This is the first contact recommended in situations of heightened crisis, including suicidal thoughts.

Helpline for Children and Youth – 116 111

Foundation We Give Children Strength. Free, active 24 hours a day. For individuals under 18 years of age. Consultants are trained to work with young people in crisis.

Emergency number 112

In situations of immediate life threat (suicide attempt, rapidly deteriorating mental state), call 112 or go to the emergency room of the nearest hospital. Every hospital in Poland is obliged to provide emergency assistance, regardless of insurance.

Psychiatric help within NFZ

Since 2019, psychiatric clinics for adults are available without a referral. You just need to register at the chosen facility. Waiting times can be long (from a few weeks to several months), but in urgent cases, an intervention visit is possible. Mental Health Centers in Poland operate on a rapid access model.

Frequently Asked Questions

Does CBD treat depression?

No. CBD is not a registered antidepressant and does not replace SSRIs, SNRIs, or psychotherapy. Most evidence comes from animal models, where CBD showed effects similar to imipramine through activation of the 5-HT1A receptor (Linge et al., Neuropharmacology, 2016). There is a lack of large RCTs in humans with clinical depression.

How does CBD affect mood at a biological level?

CBD indirectly activates the serotonin receptor 5-HT1A, modulates anandamide by inhibiting FAAH, and increases BDNF expression in the prefrontal cortex and hippocampus in animal models (Sales et al., Mol Neurobiol, 2018). These are three pathways that are also targets of classical antidepressants, but evidence in humans is preliminary.

Can antidepressants be discontinued and CBD taken instead?

This should not be done independently. Sudden discontinuation of SSRIs or SNRIs risks withdrawal syndrome and relapse of depressive episodes. CBD inhibits CYP3A4 and CYP2C19 enzymes in the liver, which may increase the concentration of many antidepressants in the blood (Skelley et al., J Am Pharm Assoc, 2020). Any change requires the approval of a psychiatrist.

What doses of CBD appear in studies on mood and anxiety?

The most commonly used doses in RCTs and case series range from 25-300 mg daily. In the retrospective study of the Permanente Journal 2019, a dose of 25-75 mg daily reduced HAM-A scores in 79% of patients after one month (Shannon et al., Permanente Journal, 2019). Anxiolytic doses are not registered as therapy for depression.

Does CBD interact with SSRIs and SNRIs?

Yes. CBD is an inhibitor of CYP3A4, CYP2C9, and CYP2C19, which may raise the levels of sertraline, citalopram, escitalopram, fluoxetine, or venlafaxine (Skelley et al., J Am Pharm Assoc, 2020). Clinically, this increases the risk of serotonin syndrome, sedation, and nausea. Combining requires psychiatric supervision and monitoring of symptoms.

What does science say about CBD in severe depressive episodes?

There is a lack of data from large RCTs for severe depression (MDD). There are individual pilot studies and case series available. The review by Crippa et al. (Curr Pharm Des, 2018) indicates the anxiolytic and antidepressant potential of CBD, but the authors emphasize that evidence in humans is preliminary and does not justify clinical use as monotherapy.

Does CBD support neurogenesis?

In animal models, CBD increases BDNF expression and supports neurogenesis in the hippocampus (Sales et al., Mol Neurobiol, 2018). These are the same pathways activated by fluoxetine in rodents. However, we do not have evidence that this effect occurs in humans taking CBD orally at typical doses of 25-100 mg daily.

When should one see a psychiatrist instead of reaching for CBD?

Whenever a depressed mood lasts more than 2 weeks, resignation or suicidal thoughts arise, sleep and appetite disturbances occur. According to WHO reports, depression affects about 280 million people worldwide and is one of the leading causes of disability (WHO, 2023). CBD is not a substitute for psychiatric treatment.

Are there active Polish helplines for mental crises?

Yes. Free Helpline for Adults in Emotional Crisis: 116 123 (active daily). Helpline for Children and Adolescents of the We Give Children Strength Foundation: 116 111. Support Center for People in Mental Crisis: 800 70 2222 (24/7). In life-threatening situations, call 112.

Can CBD worsen depression?

In some individuals, yes. The most commonly reported side effects are drowsiness, apathy, dry mouth, and diarrhea (Iffland & Grotenhermen, Cannabis and Cannabinoid Research, 2017). Sedation may mask symptoms or hinder activity, which in a person in a depressive episode deepens withdrawal. Therefore, constant contact with the attending physician is necessary.

Summary – what do we really know about CBD and depression in 2026?

After six years of intensive research development, the position of CBD in depression is as follows. We have a coherent biological hypothesis: 5-HT1A, BDNF, anandamide, neurogenesis. We have preclinical data in animals that confirm it. We have individual studies in humans, mainly in anxiety with accompanying depression. There is a lack of large RCTs for MDD as the primary diagnosis.

CBD is not a medication for depression. It may be considered as an adjunct to primary therapy in a stable patient with anxiety or sleep problems, after consulting with a psychiatrist and considering interactions with antidepressants. This is a very narrow niche, not a broad recommendation.

If you are struggling with a low mood, the first step is to see a psychiatrist or a primary care physician, not a store selling oils. Treating depression is effective, but it requires time and consistency. SSRIs, psychotherapy, physical activity, sleep, diet – these are proven pillars of therapy. CBD can at best be an adjunct if deemed appropriate by your doctor.

The cannabis market has an important educational role. We can help the reader understand where pharmacology ends and marketing begins. A better decision starts with good information. We hope this article has provided enough for you to engage in a conversation with your attending physician consciously and without illusions.

Scientific sources

• Linge R., Jiménez-Sánchez L., Campa L., et al. (2016). Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology, 103, 16-26.
• Sales A.J., Crestani C.C., Guimarães F.S., Joca S.R.L. (2018). Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels. Molecular Neurobiology, 55, 7869-7878.
• Shannon S., Lewis N., Lee H., Hughes S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente Journal, 23, 18-041.
• Crippa J.A., Guimarães F.S., Campos A.C., Zuardi A.W. (2018). Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Current Pharmaceutical Design.
• Pinto J.V., Saraf G., Frysch C., et al. (2020). Cannabidiol as a treatment for mood disorders: A systematic review. Journal of Cannabis Research.
• Skelley J.W., Deas C.M., Curren Z., Ennis J. (2020). Use of cannabidiol in anxiety and anxiety-related disorders. Journal of the American Pharmacists Association, 60(1), 253-261.
• Iffland K., Grotenhermen F. (2017). An Update on Safety and Side Effects of Cannabidiol. Cannabis and Cannabinoid Research, 2(1), 139-154.
• Russo E.B. (2016). Clinical Endocannabinoid Deficiency Reconsidered. Cannabis and Cannabinoid Research.
• Bergamaschi M.M., Queiroz R.H., Chagas M.H., et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36, 1219-1226.
• WHO. (2023). Depressive disorder (depression). World Health Organization Fact Sheets.
• WHO ICD-11. (2022). Depressive disorders (6A70-6A7Z). International Classification of Diseases, 11th Revision.
• APA. (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Association.
• NICE NG222. (2022). Depression in adults: treatment and management. National Institute for Health and Care Excellence.
• FDA. (2018). FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. U.S. Food & Drug Administration.

This article is for informational and educational purposes and does not constitute medical advice. Depression is a serious illness requiring diagnosis and psychiatric treatment. CBD is not a registered medication for depression or mood disorders. It does not replace SSRIs, SNRIs, TCAs, psychotherapy, or other treatment methods recommended by NICE and APA. Before starting to use CBD, especially alongside antidepressants, consult with your attending physician or pharmacist. During pregnancy, breastfeeding, and in individuals under 18 years of age, the use of CBD without medical indications is not recommended.

In crisis, call:
– Adult Helpline: 116 123
– Support Center 24/7: 800 70 2222
– Children's and Youth Helpline: 116 111
– Emergency number: 112

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 26, 2026
Last update: April 26, 2026
Next review: April 26, 2027